7 June 2016

Smith and Nephew

Smith & Nephew (SN) is a global medical devices business operating in three main segments: Orthopaedics, Endoscopy and Advanced Wound Management (AWM)

Group 10Created with Sketch.
Price
£11.79
Group 11Created with Sketch.
52 Week High-Low
£12.20 - £10.41
Page 1Created with Sketch.
Net Yield
1.8%
Group 12Created with Sketch.
Hist / Pros Per
37.6 - 19.8
Page 1Created with Sketch.
Equity Market Cap
£10,544

Smith & Nephew (SN) is a global medical devices business operating in three main segments: Orthopaedics, Endoscopy and Advanced Wound Management (AWM). Traditionally SN relied on demand from the developed markets, and whilst they continue to deliver mid-single digit revenue growth, which is no mean feat in these markets, management are concentrating on the emerging economies. Integral to SN maintaining its high rating is tackling the issue of the loss of market share experienced in its core hips and knees segment over the last two to three years. Here, SN has launched a lower cost, streamlined and potentially price disruptive new range in Syncera. 

Elsewhere in the Group, their Sports Medicine division is beginning to reap the benefits of the recent acquisition of ArthoCare after some subdued performance throughout most of 2015. AWM has been mixed of late with double digit growth in Devices entirely offset by volatility in Bioactives. I believe the core business to be robust throughout the cycle and the shares enjoy support from a reasonable yield and ever-present bid rumours.


Also in this issue

Much has been written about the difficulty young adults have making their first home purchase. It’s true that without substantial help with a larger deposit, it’s almost impossible to save much of a…

There are two sets of accounting standards which dominate the world. The IFRS Foundation has oversight of the International Accounting Standards Board who publish the IFRS or International Financial…